

Anti-Gingivitis and Anti-Osteoclastogenesis Effects of Ethanol Extract from *Hippophae rhamnoides* L. Fruits in IL-1 β -Induced Human Gingival Fibroblasts and RANKL-Induced RAW 264.7 Macrophages


Seo-Yun Jang^{1,2}, So-Won Heo^{1,3}, Chae-Won Lee^{1,2}, Kyung-Sook Chung¹, Hyun-Il Jung⁴, Geon-I-Seo Eom⁴, Eun Kyung Choi⁴, Ki Woong Yu⁴, and Kyung-Tae Lee^{1,2,3*}

¹Department of Pharmaceutical Biochemistry, College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea

²Department of Fundamental Pharmaceutical Science, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea

³Department of Life and Nanopharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea

⁴Dongkook Pharmaceutical Co., Seoul 06072, Republic of Korea



Received: January 7, 2026
Accepted: February 4, 2026
Published: February 26, 2026

*Corresponding author
E-mail: ktleee@khu.ac.kr

Supplementary data for this paper are available online only at <http://jmb.or.kr>.

Funding: This research was funded by Dongkook Pharmaceutical Co., grant number (KHU-Dongkook Pharmaceutical Co.-20232776).

Data Availability: The data analyzed in this study are available from the first or corresponding author upon reasonable request.

Conflict of Interest: The authors have no financial conflicts of interest to declare.

eISSN 1738-8872

Copyright © 2026 by the authors. Licensee KMB. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.

Periodontal disease is a chronic inflammatory disorder that irreversibly damages soft tissue. Current treatment options often face challenges such as drug resistance, highlighting the need for alternative therapies with fewer side effects. This study was conducted to explore the therapeutic potential of *Hippophae rhamnoides* extracted using 70% ethanol (DKB140, with kaempferol as the marker compound) for periodontal disease treatment. The anti-gingivitis and anti-periodontitis effects of DKB140 were demonstrated in RAW 264.7 macrophages and human gingival fibroblasts (hGF-1) using enzyme-linked immunosorbent assay (ELISA), reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and western blot analysis by investigating the NLRP3 signaling pathway and its inhibitory effects on matrix metalloproteinase (MMP) expression and osteoclast differentiation. In RAW 264.7 macrophages, DKB140 attenuated the production of prostaglandin E₂ and COX-2 mRNA expression. Furthermore, DKB140 inhibited inflammatory cytokine (IL-6, IL-8, and IL-1 β) production and mRNA expression. In hGF-1s, DKB140 downregulated prostaglandin E₂, COX-2, and inflammatory cytokine levels. Mechanistic investigations demonstrated that the anti-gingivitis effects of DKB140 were mediated through the NF- κ B/MAPK/NLRP3 signaling pathway. These findings were confirmed using an NLRP3 inhibitor. Moreover, DKB140 reduced the expression of collagenases (MMP-1 and MMP-13), gelatinases (MMP-2 and MMP-9), and stromelysins (MMP-3 and MMP-10) in hGF-1s. Furthermore, DKB140 decreased the expression of nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1), dendritic cell-specific transmembrane protein (DCstamp), and cathepsin K (CTSK), which are responsible for osteoclast differentiation in receptor of nuclear factor kappa-B ligand (RANKL)-stimulated osteoclasts. These findings suggest that DKB140 can function as a dual-functional agent with anti-gingival and anti-periodontal properties.

Keywords: *Hippophae rhamnoides* L., Gingivitis, Periodontitis, NLRP3, Matrix metalloproteinase

Introduction

Gingivitis, a prevalent oral disease, arises from multifactorial etiologies such as plaque, genetics, specific infections, lesions, and nutritional and metabolic diseases [1]. Oral diseases contribute to the

activation of immune cells, which subsequently triggers an inflammatory response and exacerbates gingivitis progression [2]. Even mild gingival inflammation, if left unmanaged, can progress to chronic inflammation, periodontitis, and gradual tissue damage in the surrounding teeth [2]. Furthermore, chronic gingivitis exacerbates the host condition by causing an imbalance in microbial populations within the oral cavity and contributes to the progression of systemic inflammatory responses [3]. In addition, given the challenges in achieving complete resolution of periodontitis, early intervention and preventive management of gingivitis have become critical strategies for mitigating the onset and progression of periodontitis [4]. The use of antibiotics, either alone or in combination, to treat periodontitis is limited by the emergence of antibiotic resistance [5]. To overcome these limitations, research is being conducted on the pathogenesis of periodontitis, focusing on the production of pro-inflammatory cytokines, the macrophages that induce them, and the underlying signaling mechanisms [5].

The nucleotide-binding oligomerization domain and leucine-rich repeat-containing protein 3 (NLRP3) inflammasome are pivotal inflammatory mediators associated with gingivitis and are involved in the development of chronic oral diseases through their activation [6]. These inflammatory complexes are secreted by gingival fibroblasts (GF), a major component of periodontal tissue, and play a pivotal role in maintaining oral health [6]. Furthermore, the NLRP3 inflammasome is closely associated with nuclear factor kappa B (NF- κ B), which controls inflammatory signaling pathways by modulating its expression [7]. The regulation of NF- κ B expression plays a pivotal role in controlling inflammation-induced bone destruction caused by severe periodontitis, and mitogen-activated protein kinase (MAPK) signals induce disease progression [8]. Thus, recent research has focused on these mechanisms to develop effective strategies for alleviating gingivitis and periodontitis [7-9].

Plant extracts, which are associated with few adverse effects, have gained attention as promising candidates for long-term use in the management of gingivitis and periodontitis [10]. Although some studies explored the potential benefits of various plant extracts in alleviating gingivitis, no plant with a definitive mechanism or efficacy against oral diseases has been identified [10, 11]. Among these plant extracts, sea buckthorn fruit (*Hippophae rhamnoides* L.), which is a major research target in cosmetics and functional foods, is widely distributed in Northwestern Europe and Asia under optimal cultivation conditions [12]. Although *H. rhamnoides* L. is rich in various bioactive compounds and exhibits various pharmacological activities, such as counteractive effects of inflammation, psoriasis [13], and skin aging [14], and effects of brain neuroprotection [15], its therapeutic potential for gingivitis remains unexplored. Accordingly, we hypothesized that DKB140, a 70% ethanol extract from the fruits of *H. rhamnoides* L., would demonstrate therapeutic efficacy against gingivitis and periodontitis based on these established bioactivities. Kaempferol, which is abundant in DKB140, has been previously demonstrated as a multifunctional molecule exhibiting antioxidant, neuroprotective, and anticancer activities [16]. We examined the anti-inflammatory, anti-gingival, and anti-periodontitis effects of DKB140 in RAW 264.7 macrophages and human GFs (hGF-1s).

Materials and Methods

Materials

Fibroblast medium, fibroblast growth supplement (FGS), fetal bovine serum (FBS), penicillin and streptomycin (PS), and hGF-1 were purchased from ScienCell (USA); FBS, PS, and Dulbecco's modified Eagle's medium (DMEM), from Hyclone (USA); RAW 264.7 macrophages from Republic of Korean Cell Line Bank (Republic of Korea); MCC950 from Invitrogen (USA); lipopolysaccharide (LPS), and receptor of nuclear factor kappa-B ligand (RANKL), and chemicals from Sigma-Aldrich (USA), and recombinant human IL-1 β from R&D Systems (USA).

DKB140 Preparation

The fruits of *H. rhamnoides* L. used in this study were harvested in Qinghai (China) and identified by Prof. Young Pyo Jang (Kyung Hee University; Seoul, Republic of Korea). A specimen voucher (CB17-230201) has been deposited in the material bank of Puredia LIMITED (China) and Dongkook Pharmaceutical (Republic of Korea). The plant material was Good Agricultural Practices-certified and stored dry at 25°C. Immediately after harvesting, the fruits of the plants were processed and dried on the same day to preserve freshness and prevent the degradation of nutritional components. These dried fruits were prepared and provided by Puredia LIMITED. Air-dried *H. rhamnoides* L. fruits were pulverized and extracted with 70% ethanol (1:7, w/v) by refluxing at 70–80°C for 1.5 h under static conditions. The extraction was repeated twice, and the combined filtrates were concentrated and spray-dried, yielding an extract of 2.43%. The powder contained 800 mg/g of proanthocyanidins, initially considered for use as quality-control markers for DKB140. However, due to their structural heterogeneity, instability, and analytical challenges, proanthocyanidins were deemed unsuitable. Consequently, kaempferol, a stable and quantifiable constituent, was selected as the analytical marker and measured using an Agilent 1260 Infinity II HPLC system equipped with a PDA detector (Agilent 1260 WR G7115A UV/Vis Detector, USA). The reverse phase Luna C18 column (125 mm $\times$ 4.0 mm I.D., 5 μ m, Phenomenex, USA) was used at 25°C. The mobile phase (v/v) consisted of 0.5% phosphoric acid (pH 2.0) in water (A) and methanol (B). A linear binary mobile phase solvent gradient was used as follows: 60% A at 0 min, 45% A at 20 min, 0% A at 21 min, and 60% A at 26 min. In total, the sample solution (10 μ l) was injected for each run at a flow rate of 1.0 ml/min, and the analysis was monitored at 370 nm. A standard curve was established using kaempferol dissolved in methanol at a final concentration of 4 to 12 μ g/ml. The DKB140 chromatogram exhibited a characteristic peak at a retention time of 19.145 min, which was identified as kaempferol. This result indicated that kaempferol is the major component of DKB140 (9.42 mg/g; Fig. 1).

Cell Culture Conditions and the Dose of the Sample

hGF-1s were incubated in fibroblast medium (2% FBS, 1% FGS, and 1% PS) and treated with DKB140 (3, 6, or 12 μ g/ml) and IL-1 β (10 ng/ml) at various times. RAW 264.7 macrophages were incubated in DMEM (10% FBS and 10% PS) and treated with DKB140 (3, 6, or 12 μ g/ml), LPS (5 ng/ml), or RANKL (100 ng/ml) at various times.

MTT Assay

hGF-1s were seeded into 24-well plates (2 $\times$ 10⁵ cells/ml) overnight. The cells were then serum-starved in medium containing 0.5% FBS for 18 h. Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution (5 mg/ml stock). RAW 264.7 macrophages' viability was assessed as previously described [17]. hGF-1s or RAW 264.7 macrophages were treated with DKB140 (3, 6, or 12 μ g/ml) and IL-1 β (10 ng/ml) or LPS (5 ng/ml) in a 24-well plate for 24 h.




Fig. 1. HPLC chromatograms of DKB140 and kaempferol. HPLC analysis of (A) blank solution (methanol), (B) DKB140 (1 mg/ml), and (C) standard solution of kaempferol (8.0 µg/ml).

Determination of PGE₂ and Cytokine Production

hGF-1s (2×10^5 cells/ml) or RAW 264.7 macrophages (2×10^5 cells/ml) were treated with DKB140 and IL-1 β or LPS for 24 h. The supernatant of PGE₂, IL-6, IL-1 β , TNF- α , and IL-8 production was determined using PGE₂ (Enzo Life Sciences, USA) or human or mouse Duoset ELISA kits (R&D Systems, USA) at 450 nm absorbance.

Table 1. Primer sets utilized in RT-qPCR.

		Forward sequence	Reverse sequence
Human gene	COX-2	TGCGCCTTTTCAAGGATGGA	CGCAGCCAGATTGTGGCATA
	IL-6	CAATGAGGAGACTTGCCTGG	GCACAGCTCTGGCTTGTTC
	IL-1 β	AGATGATAAGCCCACTCTACAG	ACATTGAGCAGGACTCTC
	MMP-1	GCCCAGGTATTGGAGGGGAT	AGGGTACATCAAAGCCCCGA
	MMP-2	ACCGCGACAAGAAGTATGGC	CCACTTGCAGTCATCATCGT
	MMP-3	ATTCCATGGAGCCAGGCTTTC	CATTTGGGTCAAACCTCAACTGTG
	MMP-9	CGATGACGAGTTGTGGTCCC	TCGTAGTTGGCCGTGGTACT
	MMP-10	GGCTCTTCACTCAGCCAAC	CTCAGATCCCGAAGGAACAG
	MMP-13	AGTTTGACAGAGCGCTACCTGAGAT	TTTGCCAGTCACCTCTAAGCCGAA
	TNF- α	TCTCTCTAATCAGCCCTCTG	CAGATAGATGGGCTCATACC
Mouse gene	GAPDH	ACATCAAGAAGGTGGTGAAG	GTAGCCAAATTTCGTTGTCAT
	COX-2	TGCTGTACAAGCAGTGGCAA	GCAGCCATTTCTCTCTCC
	CTSK	AGTGTGGTGGTGGGCTATG	GGCTGGCTGGAATCAGATCT
	DCstamp	TTTTCTAAGGCTTTGGGGG	ACAGAAGAGAGCAGGGCAAC
	IL-6	GAGGATACCACTCCCAACAGACC	AAGTGCATCATCGTTGTTTCATACA
	IL-1 β	ACCTGCTGGTGTGTGACGTT	TCGTTGCTTGGTTCTCCTTG
	NFATc1	GGGTGAGTGTGACCGAAGAT	GGAAGTCAGAAGTGGGTGGA
	TNF- α	AGCACAGAAAGCATGATCCG	CTGATGAGAGGGAGGCCATT
	β -actin	ATCACTATTGGCAACGAGCG	TCAGCAATGCCTGGGTACAT

Table 2. Antibodies catalog number.

Purchase	Antibody
Santa Cruz Biotechnology Inc. (USA)	β -actin (sc-81178), caspase-1 (sc-56036), c-Fos (sc-253), COX-2 (sc-376861), I κ B α (sc-371), JNK (sc-7345), p65 (sc-8008), p-c-Jun (sc-822)
Cell signaling (USA)	ASC (#13833), c-Jun (#9165), ERK (#9102), NLRP3 (#15101), p-c-Fos (#5348), p-ERK (#4377), p-I κ B α (#9246), p-JNK (#4668), p38 (#9212), p-p38 (#9215), p-p65 (#3033)

ASC: apoptosis-associated speck-like protein containing a CARD

Real-Time Quantitative PCR (RT-qPCR)

RNA from hGF-1s (2×10^5 cells/ml) and RAW 264.7 macrophages (3×10^5 cells/ml) was obtained using Easy blue kits. cDNA was synthesized using 0.5 mg/ml random oligonucleotide primers and TOPscript RT DryMIX. PCR was performed for 50 cycles under the following conditions: denaturation at 95°C for 5 sec, annealing at the respective T_m (°C) for 10 sec, and elongation at 72°C for 20 sec. Amplified RNA-SYBR green complexes were detected using a QuantStudio 1 Real-Time PCR Instrument (Thermo Fisher Scientific, USA). The primer sequences are listed in Table 1, which were designed using Primer3.

Western Blot Analysis

Proteins from hGF-1s (1.5×10^5 cells/ml) were obtained using the PRO-PREP protein extraction solution. Protein concentrations were determined using the Bradford reagent (Bio-Rad, USA) following the manufacturer's instructions. The proteins were resolved on a 10–15% polyacrylamide gel and transferred onto a polyvinylidene difluoride (PVDF) membrane (Merck Millipore, USA). The PVDF membrane was incubated in 1–5% skim milk with a primary antibody at 4°C for 18 h. The immunoblotted membrane was washed three times with Tris-buffered saline/Tween 20 (TBS/T) and incubated with a secondary antibody at 25°C for 2 h, then the proteins were detected using an ECL chemiluminescence substrate. The antibodies used are listed in Table 2.




Fig. 2. Effects of DKB140 on expression of inflammatory mediators in LPS-treated RAW 264.7 macrophages. (A) PGE₂ production and cell viability, (B) COX-2 mRNA expression, (C–H) IL-6, IL-1β, and TNF-α production and mRNA expression levels in LPS-treated RAW 264.7 macrophages. Data are presented as the means ± SEM of three independent experiments. #*P* < 0.05 vs. CON; **P* < 0.05, ***P* < 0.01, ****P* < 0.001 vs. LPS-treated cells.

Tartrate-Resistant Acid Phosphatase (TRAP) Staining Assay

RAW 264.7 macrophages (0.5×10^5 cells/ml) were co-treated with DKB140 and RANKL. Sample treatments were repeated on days 2, 4, and 6. TRAP staining was performed on RAW 264.7 macrophages harvested on day 7 with a TRACP & ALP double-stain kit (TaKaRa, Japan). A microscope (OLYMPUS, Japan) was used to observe osteoclast differentiation.

Statistical Analysis

Each result is expressed as means $\pm$ standard error of the mean (SEM). Statistical significance ($P < 0.05$) was performed using one-way ANOVA and Dunnett's post hoc test through software, GraphPad Prism 8.0.2. (GraphPad Software Inc., USA).

Results

DKB140 Decreases Inflammatory Mediators in LPS-Induced RAW 264.7 Macrophages

As shown in Fig. 2A, DKB140 was not cytotoxic at any of the tested concentrations (3, 6, or 12 μ g/ml), and treatment with DKB140 downregulated inflammatory mediators, including prostaglandin E_2 (PGE₂) production (Fig. 2A). Notably, the inhibitory effect of DKB140 (12 μ g/ml) towards PGE₂ (53.07%) was comparable to that of the positive control NS398 (46.44%; Fig. 2A), accompanied by suppression of COX-2 mRNA expression (Fig. 2B). Additionally, DKB140 reduced the production (Fig. 2C and 2D) and mRNA expression (Fig. 2F and 2G) of IL-6 and IL-1 β . However, the production and mRNA expression of TNF- α were mildly reduced by DKB140 (Fig. 2E and 2H). These findings demonstrate that DKB140 exhibited anti-inflammatory properties in LPS-induced RAW 264.7 macrophages.

DKB140 Reduces Inflammatory Mediators in IL-1 β -Induced hGF-1 Cells

Based on the ability of DKB140 to target specific cytokines (IL-6 and IL-1 β), we hypothesized that the extract could reduce gingival inflammation and evaluated its anti-inflammatory effects on hGF-1s. Treatment of hGF-1s with DKB140 (12 μ g/ml) not only exhibited non-cytotoxic effects but also significantly decreased PGE₂ production (11.24%) to a level comparable to that of the positive control NS398 (15.34%; Fig. 3A). Furthermore, DKB140 significantly downregulated COX-2 mRNA and protein expression (Fig. 3B and 3C) in IL-1 β -induced hGF-1s. DKB140 also suppressed the IL-1 β -induced production of IL-6, IL-8, and IL-1 β (Fig. 3D–3F). Consistent with these results, the mRNA expression




Fig. 3. Effects of DKB140 on the production and expression of inflammatory mediators in IL-1 β -treated hGF-1s. (A) PGE₂ production and cell viability, (B and C) mRNA or protein expression of COX-2, (D–I) IL-6, IL-8, and IL-1 β production and mRNA expression levels in IL- β -treated hGF-1s. Data are presented as the means $\pm$ SEM of three independent experiments. # $P < 0.05$ vs. CON; * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ vs. IL-1 β -treated cells.

of IL-6, IL-8, and IL-1 β was downregulated to approximately control levels at 12 μ g/ml of DKB140 (Fig. 3G–3I). These data indicate that DKB140 exerts anti-inflammatory effects by suppressing inflammatory mediators in both macrophages and hGF-1s.

DKB140 Suppresses the NLRP3 Inflammasome in IL-1 β -Induced hGF-1s

To identify the fundamental processes mediating the anti-inflammatory response to DKB140, the NLRP3 inflammasome signaling cascade was investigated. As shown in Fig. 4A, IL-1 β stimulation led to increased expression of cleaved caspase-1 and NLRP3; however, treatment with DKB140 reduced the expression of both proteins. ASC expression was upregulated by IL-1 β stimulation, whereas DKB140 treatment did not affect ASC expression in hGF-1s (Fig. 4A). To verify the effects of DKB140 on the NLRP3 signaling pathway, the expression of cleaved caspase-1 was




Fig. 4. Effects of DKB140 on the NLRP3 signaling pathway in IL-1 β -treated hGF-1s. (A) Protein expression of NLRP3 inflammasome; hGF-1s were pre-treated with MCC950 (1 h), and DKB140 (1 h), and then stimulated with IL-1 β (5 h). (B and C) Protein expressions of cleaved-caspase-1 and COX-2 in MCC950, DKB140, and IL-1 β treatment groups in hGF-1s. Data are presented as the means $\pm$ SEM of three independent experiments. $^{\#}P < 0.05$, $^{***}P < 0.001$ vs. CON; $^{***}P < 0.001$ vs. IL-1 β -treated cells; $^{+++}P < 0.001$ vs. DKB140 and IL-1 β co-treated cells.




Fig. 5. Effects of DKB140 on NF- κ B/MAPK signaling pathways in IL-1 β -treated hGF-1s. (A and B) MMP-1 and -13 collagenases, (C and D) MMP-2 and -9 gelatinases, and (E and F) MMP-3 and -10 stromelysins mRNA expression in IL-1 β -treated hGF-1s. (G) Protein expression of the NF- κ B, (H) AP-1, (I) MAPK signaling pathway in IL-1 β -treated hGF-1s. Data are presented as the means $\pm$ SEM of three independent experiments. $^{\#}P < 0.05$ vs. CON; $^{*}P < 0.01$, $^{***}P < 0.001$ vs. IL-1 β -treated cells.




Fig. 6. Effects of DKB140 on osteoclasts and the expression of osteoclastogenesis mediators in RANKL-treated RAW 264.7 macrophages. (A) Cell viability, (B) Number of osteoclasts, (C–E) NFATc1, DCstamp, and CTSK osteoclastogenesis mediator mRNA expression in RANKL-treated RAW 264.7 macrophages. Data are presented as the means $\pm$ SEM of three independent experiments. # $P < 0.05$ vs. CON; * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ vs. RANKL-treated cells.

assessed following treatment with MCC950, an NLRP3-specific inhibitor. In all groups treated with MCC950, cleaved caspase-1 expression was prevented compared with that in the untreated group, particularly in the group co-treated with DKB140, which exhibited pronounced suppression of cleaved caspase-1 expression in IL-1 β -induced hGF-1s (Fig. 4B). Moreover, similarly to the results observed with cleaved caspase-1 following treatment with the NLRP3 inhibitor, COX-2 expression was reduced following co-treatment with DKB140 and MCC950 (Fig. 4C). These findings suggest that the NLRP3 inflammasome modulation by DKB140 is associated with attenuation of inflammatory responses in IL-1 β -induced hGF-1s.

DKB140 Inhibits NF- κ B/MAPK Signaling Pathways in IL-1 β -Induced hGF-1s

After confirming the suppressive effects on inflammatory mediators and NLRP3 inflammasome of DKB140 in hGF-1s, the expression levels of MMP, which serve as a key indicator of tissue damage, were assessed to determine the therapeutic impact of DKB140. As shown in Fig. 5A and 5B, the mRNA expression levels of MMP-1 and -13, which are involved in collagen degradation, MMP-2 and -9 (implicated in gingival tissue damage; Fig. 5C and 5D), and MMP-3 and -10 (maintain soft tissue integrity; Fig. 5E and 5F) were upregulated by IL-1 β stimulation. However, DKB140 treatment attenuated the inflammation-induced increase in the mRNA expression of MMP-1, -13, -2, -9, -3, and -10. To examine the mechanism underlying the anti-inflammatory action of DKB140, we assessed NF- κ B, known to regulate MMPs expression, in hGF-1s. IL-1 β -induced p65 phosphorylation and I κ B α degradation were recovered by DKB140, whereas phosphorylation of I κ B α was slightly decreased only at high DKB140 concentrations (Fig. 5G). As shown in Fig. 5H, DKB140 treatment resulted in a significant reduction in p-c-Fos levels, whereas the total form remained consistent, indicating that the observed changes were limited to phosphorylation. In contrast, both the phosphorylated and total forms of c-Jun were downregulated following DKB140 treatment, demonstrating a change in the overall expression of IL-1 β -induced hGF-1s. Moreover, p-p38 and p-ERK expression levels were decreased by DKB140, but treatment with DKB140 did not affect p-JNK and the total expression of MAPK in IL-1 β -induced hGF-1s (Fig. 5I). These data show that DKB140 exerted anti-gingival effects by suppression of MMPs expression via regulating the NF- κ B/MAPK pathways in IL-1 β -induced hGF-1s.

DKB140 Modulates Osteoclastogenesis in RANKL-Induced RAW 264.7 Macrophages

We next evaluated the effect of DKB140 on periodontal tissues. As shown in Fig. 6A and 6B, DKB140 treatment suppressed osteoclast differentiation without inducing cytotoxicity in RANKL-stimulated RAW 264.7 macrophages. As shown in Fig. 6C–6E, treatment with RANKL increased the expression of nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1), dendritic cell-specific transmembrane protein (DCstamp), and cathepsin K (CTSK), which are key mediators of osteoclastogenesis, whereas DKB140 treatment suppressed this expression. These results show that DKB140 has potential anti-periodontitis effects in RANKL-induced RAW 264.7 macrophages via inactivation of differentiation-induced gene expression.

Discussion

The regulation of macrophages, the central effector immune cells involved in inflammatory responses, is essential for preserving host homeostasis [18]. In periodontal disease, macrophages not only phagocytose pathogens, but also contribute to immune responses against gingival

and periodontal tissue damage by secreting cytokines and PGE₂, which in turn activate osteoclasts [19]. To investigate the anti-inflammatory mechanism of DKB140, we evaluated its effect on LPS-induced RAW 264.7 cells. A previous study demonstrated that an ethanol extract of buckthorn fruit (*H. rhamnoides* L.) exhibited notable anti-inflammatory activity [20]. Consistently, our results showed that DKB140 suppressed IL-6 and IL-1 β production, which are key factors in periodontal disease in both IL-1 β -induced hGF-1s and RANKL-induced RAW 264.7 macrophages [21]. In contrast, although DKB140 significantly inhibited TNF- α mRNA expression, it did not result in a statistically significant reduction in TNF- α production. This discrepancy suggests that the inhibitory effect of DKB140 on TNF- α transcription may have been too modest to substantially affect the subsequent translation and secretion stages. Nevertheless, given the robust suppression of other major pro-inflammatory mediators, our findings still suggest that DKB140 is effective against periodontitis, warranting further investigation of its effects in hGF-1s.

Gingivitis is an early-stage manifestation of periodontal disease characterized by mild inflammatory symptoms such as bleeding, swelling, and painful gums [22]. This condition can readily develop due to various factors, and the management of gingivitis is essential, given that it can progress to more severe periodontitis [22]. According to a previous study, chronic gum inflammation can lead to destruction of the alveolar bone, periodontal fascia, and periodontal ligament, impacting the supporting tissues of the teeth [23]. Furthermore, periodontal inflammatory mediators and toxins may enter the bloodstream and contribute to systemic diseases such as cardiovascular disease [24] and neurodegeneration [25]. GFs are among the most abundant cells in the gingival tissue and are vital for maintaining tissue structure and integrity [26]. Excessive activation of GFs by uncontrolled inflammatory mediators can lead to chronic inflammation and tissue damage and, in severe cases, may initiate systemic inflammatory responses [26]. The inflammatory cytokine IL-1 β , which is used as an inducer of GFs, elicits a much stronger inflammatory response than *Porphyromonas gingivalis* LPS [27]. Several studies validated the use of IL-1 β as an inflammation inducer in hGF-1s, with consistent findings of increased expression of MMPs and inflammatory mediators, which align with our results [28, 29]. Regarding the chemical composition of the DKB140 extract used to suppress these inflammatory responses, we identified kaempferol as a marker compound due to its high stability and distinct peak in HPLC analysis. Kaempferol has been reported to exhibit anti-periodontitis activity [30], and proanthocyanidins, which are abundantly present in DKB140, are known to possess anti-inflammatory and tissue-protective properties in periodontal environments [31-33]. Therefore, the therapeutic effects of DKB140 may be attributed, at least in part, to the presence of kaempferol together with other bioactive polyphenolic constituents, including proanthocyanidins, although their individual contributions and potential interactions were not directly evaluated in the present study. The synergistic potential of these compounds will be investigated in further study.

MMPs are proteolytic enzymes that degrade components crucial for periodontal tissue homeostasis and interact intricately with the inflammatory environment [34]. One type of MMP, collagenase (MMP-1 and -13), specifically targets collagen fibers, which are the primary components of periodontal tissue [34]. Collagenase is activated in abnormal inflammatory responses, reducing the structural integrity of the periodontal tissue and subsequently damaging the periodontal ligament and alveolar bone, and is ultimately related to periodontal breakdown [35]. MMP-2 and -9, categorized as gelatinases, are involved in the degradation of various connective tissue proteins and regulate certain inflammatory mediators during the initial stages of inflammation [36]. Stromelysins (MMP-3 and -10) degrade non-collagenous matrix (extracellular matrix) components [37]. Similar to previous studies, the MMP family in periodontal tissues, particularly within soft tissues, is a key regulatory marker of mild periodontal disease [38, 39]. Our findings demonstrate that DKB140 significantly suppressed the mRNA expression of MMPs, such as MMP-1, -13, -2, -9, -3, and -10, which were upregulated in IL-1 β -induced hGF-1s under inflammatory conditions. The remarkable reduction in MMPs by DKB140 suggests its potential to protect the soft tissue and extracellular matrix components of gingival tissue, indicating that it can protect the gingival tissue. Furthermore, the potential of DKB140 as a therapeutic agent for gingivitis was supported by its ability to modulate pivotal inflammatory pathways, suggesting a promising approach for the prevention and treatment of gingival tissue damage.

The NLRP3 inflammasome is a crucial innate immune regulator that responds to pathogens in chronic diseases such as periodontitis [40]. Inflammatory responses are triggered via activation of the NLRP3/caspase-1/IL-1 β pathway [41], and clinical studies demonstrated elevated expression of NLRP3 and IL-1 β in chronic periodontitis [42]. Activation of the NLRP3 inflammasome initiates a priming phase via NF- κ B signaling, which induces the synthesis of NLRP3 and pro-IL-1 β expression [41]. In alignment with established mechanisms, DKB140 decreased p65 activation and prevented both the degradation and phosphorylation of I κ B α . To confirm this mechanism, further cross-validation was conducted by co-treatment with DKB140 and the NLRP3 inhibitor MCC950. Our results showed that combined treatment with DKB140 and MCC950 reduced cleaved caspase-1 expression compared to treatment with DKB140 or MCC950 alone. Similarly, the expression of COX-2, a terminal inflammatory marker associated with the NLRP3 inflammasome [43], followed the same trend as that of cleaved caspase-1 reduction. These results suggest that DKB140 strongly suppresses inflammatory responses by suppressing the NLRP3 signaling pathway via a complementary mechanism rather than by competing with MCC950. Thus, additional experimental approaches such as the use of a knockout cell model are needed to clarify the role of DKB140 in inhibiting the NLRP3 inflammasome.

Additionally, although the AP-1 and MAPK pathways, which are essential inflammatory signaling pathways, are not directly involved in NLRP3 signaling in GF, they regulate the NLRP3 pathway in conjunction with NF- κ B signaling [44]. Our results revealed a particularly strong effect on p38 and ERK activation, whereas no significant effect was observed on the phosphorylation of JNK. These findings are consistent with those of previous studies, indicating a relationship between NLRP3 and p38 [45, 46]. As previously reported [47], p38 regulates AP-1 activity and downstream inflammatory signaling through its interaction with ERK. Consistent with these findings, the inhibitory effects on p-p38 and p-ERK observed in this study were evidenced by reduced phosphorylation of c-Fos and decreased expression and phosphorylation of c-Jun in the DKB140-treated *in vitro* model.

In advanced periodontitis, as inflammation escalates and pathogens accumulate in periodontal lesions, bone tissue may also be affected, leading to enhanced osteoclastogenesis and increased RANKL expression [48]. RANKL binds to RANK on osteoclast precursors and is essential for osteoclast formation and activation, primarily by promoting osteoclast differentiation [49]. Several studies evaluated the effects of therapeutic candidates on osteoclast-mediated diseases by assessing the expression of osteoclast-specific transcription factor (NFATc1) and its marker genes (TRAP, DCstamp, and CTSK). Consistent with previous findings [50, 51], DKB140 significantly arrested osteoclast differentiation, notably by suppressing TRAP, DCstamp, and CTSK expression. Although the potential of DKB140 in suppressing osteoclastogenesis has been established, the underlying mechanism remains unclear. Our study primarily focused on the normalization of hyper-inflammatory states induced by pathological stimuli, in which DKB140 exhibited significant anti-inflammatory, anti-gingivitis, and anti-periodontitis effects. However, the present study is limited by its *in vitro* experimental design, which provides only partial insight into comprehensive pharmacological mechanisms and the long-term safety profile of DKB140. Therefore, further research is needed to investigate the selective efficacy and the long-term safety of DKB140 using ligation-induced periodontitis *in vivo* models. These studies will be essential to define its therapeutic window and evaluate its

potential impact on the systemic immune responses.

Our findings demonstrate that DKB140 exhibits anti-inflammatory and anti-gingival effects, extending its potential to anti-periodontitis activity in hGF-1 cells and RAW 264.7 macrophages. The anti-inflammatory properties of DKB140 were observed in RAW 264.7 macrophages and hGF-1s as the suppression of key inflammatory mediators, including PGE₂, COX-2, and pro-inflammatory cytokines. In hGF-1s, the anti-gingivitis effects of DKB140 involved regulation of the NF- κ B/MAPK/NLRP3 signaling pathway, as well as modulation of MMP expression, which plays a critical role in maintaining gingival tissue integrity. Furthermore, DKB140 inhibited osteoclast differentiation and downregulated the associated regulatory factors in RANKL-induced RAW 264.7 macrophages. Thus, DKB140 is a promising functional food ingredient capable of managing gingivitis and periodontitis.

Author Contributions

S.-Y.J., S.-W.H., C.-W.L., and K.-T.L: Conceptualization, S.-Y.J., S.-W.H., C.-W.L: Methodology, H.-I.J., E.G.-I.-S., E.K.C., and K.W.Y: Validation, S.-Y.J: Formal analysis, S.-Y.J., S.-W.H., C.-W.L: Investigation, K.-T.L: Resources, S.-Y.J: Writing—original draft Preparation, S.-Y.J., K.-S.C., and K.-T.L: Writing—review and editing, K.-T.L: Project administration, K.-T.L: Funding acquisition. All authors have read and agreed to the published version of the manuscript.

References

- Holmstrup P, Plemons J, Meyle J. 2017. Non-plaque-induced gingival diseases. *J. Clin. Periodontol.* **45**: S28-S43. <https://doi.org/10.1111/jcpe.12938>.
- Murakami S, Mealey BL, Mariotti A, Chapple ILC. 2018. Dental plaque-induced gingival conditions. *J. Periodontol.* **89 Suppl 1**: S17-S27. <https://doi.org/10.1002/JPER.17-0095>.
- Trombelli L, Farina R, Silva CO, Tatakis DN. 2018. Plaque-induced gingivitis: case definition and diagnostic considerations. *J. Periodontol.* **89 Suppl 1**: S46-S73. <https://doi.org/10.1002/jper.17-0576>.
- Mombelli A. 2018. Microbial colonization of the periodontal pocket and its significance for periodontal therapy. *Periodontol.* **2000** **76**: 85-96. <https://doi.org/10.1111/prd.12147>.
- Lasica A, Golec P, Laskus A, Zalewska M, Gedaj M, Popowska M. 2024. Periodontitis: etiology, conventional treatments, and emerging bacteriophage and predatory bacteria therapies. *Front. Microbiol.* **15**: 1469414. <https://doi.org/10.3389/fmicb.2024.1469414>.
- Huang C, Zhang C, Yang P, Chao R, Yue Z, Li C, et al. 2020. Eldecacitol Inhibits LPS-Induced NLRP3 Inflammasome-Dependent Pyroptosis in Human Gingival Fibroblasts by Activating the Nrf2/HO-1 Signaling Pathway. *Drug Des. Devel. Ther.* **14**: 4901-4913. <https://doi.org/10.2147/DDDT.S269223>.
- Ye Q, Lin B, Xu P, Zhang F, Wang N, Shou D. 2024. Yunvjian decoction attenuates lipopolysaccharide-induced periodontitis by suppressing NF κ B/NLRP3/IL-1 β pathway. *J. Ethnopharmacol.* **319**: 117279. <https://doi.org/10.1016/j.jep.2023.117279>.
- Aoki T, Hiura F, Li A, Yang N, Takakura-Hino N, Mukai S, et al. 2023. Inhibition of non-canonical NF- κ B signaling suppresses periodontal inflammation and bone loss. *Front. Immunol.* **14**: 1179007. <https://doi.org/10.3389/fimmu.2023.1179007>.
- Li H, Zhong X, Li W, Wang Q. 2019. Effects of 1,25-dihydroxyvitamin D3 on experimental periodontitis and AhR/NF- κ B/NLRP3 inflammasome pathway in a mouse model. *J. Appl. Oral Sci.* **27**: e20180713. <https://doi.org/10.1590/1678-7757-2018-0713>.
- Agrawal J, Pant AB, Agrawal RK. 2024. Comparative assessment of medicinal plant extract efficacy against plaque and gingivitis: a case-control study. *J. Indian Soc. Periodontol.* **28**: 204-209. https://doi.org/10.4103/jisp.jisp_396_23.
- Wang Y, Fan Q, Xu Y, Zeng F, Liu X, Zhao D, et al. 2022. Effect of Eucommia water extract on gingivitis and periodontitis in experimental rats. *BMC Oral Health* **22**: 326. <https://doi.org/10.1186/s12903-022-02535-5>.
- Gatlan AM, Gutt G. 2021. Sea buckthorn in plant based diets. an analytical approach of sea buckthorn fruits composition: nutritional value, applications, and health benefits. *Int. J. Environ. Res. Public Health* **18**: 8986. <https://doi.org/10.3390/ijerph18178986>.
- Balkrishna A, Sakat SS, Joshi K, Joshi K, Sharma V, Ranjan R, et al. 2019. Cytokines driven anti-inflammatory and anti-psoriasis like efficacies of nutraceutical sea buckthorn (*Hippophae rhamnoides*) Oil. *Front. Pharmacol.* **10**: 1186. <https://doi.org/10.3389/fphar.2019.01186>.
- Liu X, Yuen M, Yuen T, Yuen H, Wang M, Peng Q. 2024. Anti-skin aging effect of sea buckthorn proanthocyanidins in D-galactose-induced aging mice. *Food Sci. Nutr.* **12**: 1082-1094. <https://doi.org/10.1002/fsn3.3823>.
- Cavak N, Gumustas MK, Cekic SD. 2022. The protective role of *Hippophae rhamnoides* L. on rat brain and liver tissues exposed to cold plus immobilization stress model. *Turk Neurosurg.* **32**: 587-594. <https://doi.org/10.5137/1019-5149.JTN.23766-18.3>.
- Periferakis A, Periferakis K, Badarau IA, Petran EM, Popa DC, Caruntu A, et al. 2022. Kaempferol: antimicrobial properties, sources, clinical, and traditional applications. *Int. J. Mol. Sci.* **23**: 15054. <https://doi.org/10.3390/ijms232315054>.
- Song HA, Jang SY, Park MJ, Kim SW, Kang CG, Lee JH, et al. 2024. Immunostimulation signaling via toll-like receptor 2 activation: a molecular mechanism of *Lactococcus lactis* OTG1204 *in vitro* and *in vivo*. *Nutrients* **16**: 3629. <https://doi.org/10.3390/nu16213629>.
- Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaili SA, Mardani F, et al. 2018. Macrophage plasticity, polarization, and function in health and disease. *J. Cell. Physiol.* **233**: 6425-6440. <https://doi.org/10.1002/jcp.26429>.
- Zhang P, Fan Y, Li Q, Chen J, Zhou W, Luo Y, et al. 2016. Macrophage activating factor: a potential biomarker of periodontal health status. *Arch. Oral Biol.* **70**: 94-99. <https://doi.org/10.1016/j.archoralbio.2016.06.010>.
- Baek SC, Lee D, Jo MS, Lee KH, Lee YH, Kang KS, et al. 2020. Inhibitory effect of 1,5-dimethyl citrate from sea buckthorn (*Hippophae rhamnoides*) on lipopolysaccharide-induced inflammatory response in RAW 264.7 mouse macrophages. *Foods* **9**: 269. <https://doi.org/10.3390/foods9030269>.
- Sawada S, Chosa N, Ishisaki A, Naruishi K. 2013. Enhancement of gingival inflammation induced by synergism of IL-1 β and IL-6. *Biomed. Res.* **34**: 31-40. <https://doi.org/10.2220/biomedres.34.31>.
- Trombelli L, Farina R, Silva CO, Tatakis DN. 2018. Plaque-induced gingivitis: case definition and diagnostic considerations. *J. Clin. Periodontol.* **45 Suppl 20**: S44-S67. <https://doi.org/10.1111/jcpe.12939>.
- Borsa L, Dubois M, Sacco G, Lupi L. 2021. Analysis the link between periodontal diseases and Alzheimer's disease: a systematic review. *Int. J. Environ. Res. Public Health* **18**: 9312. <https://doi.org/10.3390/ijerph18179312>.
- Mattila KJ, Pussinen PJ, Paju S. 2005. Dental infections and cardiovascular diseases: a review. *J. Periodontol.* **76**: 2085-2088. <https://doi.org/10.1902/jop.2005.76.11-S.2085>.
- Ranjan R, Abhinay A, Mishra M. 2018. Can oral microbial infections be a risk factor for neurodegeneration? A review of the literature. *Neurol. India* **66**: 344-351. <https://doi.org/10.4103/0028-3886.227315>.
- Wielento A, Lagosz-Cwik KB, Potempa J, Grabiec AM. 2023. The role of gingival fibroblasts in the pathogenesis of periodontitis. *J. Dent. Res.* **102**: 489-496. <https://doi.org/10.1177/00220345231151921>.
- Rice K, Prichard I, Tiggemann M, Slater A. 2016. Exposure to Barbie: effects on thin-ideal internalisation, body esteem, and body dissatisfaction among young girls. *Body Image* **19**: 142-149. <https://doi.org/10.1016/j.bodyim.2016.09.005>.
- Abidi AH, Abhyankar V, Alghamdi SS, Tipton DA, Dabbous M. 2022. Phytocannabinoids regulate inflammation in IL-1 β -stimulated human gingival fibroblasts. *J. Periodontol. Res.* **57**: 1127-1138. <https://doi.org/10.1111/jre.1305010.1111/jre.13050>.
- Bozkurt SB, Hakki SS, Nielsen FH. 2024. Boric acid alleviates periodontal inflammation induced by IL-1 β in human gingival fibroblasts. *J. Trace Elem. Med. Biol.* **84**: 127466. <https://doi.org/10.1016/j.jtemb.2024.127466>.

30. Li N, Wang B, Yang M, Feng M, Xu X, Xian CJ, *et al.* 2025. The multi-target action mechanism for the anti-periodontitis effect of astragali radix based on bioinformatics analysis and *in vitro* verification. *Nutrients* **17**: 627. <https://doi.org/10.3390/nu17040627>.
31. Liu X, Zang L, Yu J, Yu J, Wang S, Zhou L, *et al.* 2024. Anti-inflammatory effect of proanthocyanidins from blueberry through NF-kappabeta/NLRP3 signaling pathway in *in vivo* and *in vitro*. *Immunopharmacol. Immunotoxicol.* **46**: 425-435. <https://doi.org/10.1080/08923973.2024.2358770>.
32. Nawrot-Hadzik I, Matkowski A, Hadzik J, Dobrowolska-Czopor B, Olchowicz C, Dominiak M, *et al.* 2021. Proanthocyanidins and flavan-3-Ols in the prevention and treatment of periodontitis-antibacterial effects. *Nutrients* **13**: 165. <https://doi.org/10.3390/nu13010165>.
33. Nawrot-Hadzik I, Matkowski A, Kubasiewicz-Ross P, Hadzik J. 2021. Proanthocyanidins and flavan-3-ols in the prevention and treatment of periodontitis-immunomodulatory effects, animal and clinical studies. *Nutrients* **13**: 239. <https://doi.org/10.3390/nu13010239>.
34. Luchian I, Goriuc A, Sandu D, Covasa M. 2022. The role of matrix metalloproteinases (MMP-8, MMP-9, MMP-13) in periodontal and peri-implant pathological processes. *Int. J. Mol. Sci.* **23**: 1806. <https://doi.org/10.3390/ijms23031806>.
35. Hariharan A, Krishnamurthi S, Thamarai C, Thanya K, Parameswari D, Krithika A. 2024. Sapindus mukorossi - an effective biocleaner for removable dental prostheses? an *in vitro* study. *J. Pharm. Bioallied Sci.* **16**: S1154-S1160. https://doi.org/10.4103/jpbs.jpbs_1189_23.
36. Franco C, Patricia HR, Timo S, Claudia B, Marcela H. 2017. Matrix metalloproteinases as regulators of periodontal inflammation. *Int. J. Mol. Sci.* **18**: 440. <https://doi.org/10.3390/ijms18020440>.
37. Alotaibi DH, Altalhi AM, Sambawa ZM, Koppolu P, Alsinaidi AA, Krishnan P. 2020. The association of matrix metalloproteinase gene polymorphisms and periodontitis: an overview. *J. Pharm. Bioallied Sci.* **12**: S37-S42. https://doi.org/10.4103/jpbs.jpbs_136_20.
38. Kim YG, Lee SM, Bae S, Park T, Kim H, Jang Y, *et al.* 2021. Effect of aging on homeostasis in the soft tissue of the periodontium: a narrative review. *J. Pers. Med.* **11**: 58. <https://doi.org/10.3390/jpm11010058>.
39. Radzki D, Negri A, Kusiak A, Obuchowski M. 2024. Matrix metalloproteinases in the periodontium-vital in tissue turnover and unfortunate in periodontitis. *Int. J. Mol. Sci.* **25**: 2763. <https://doi.org/10.3390/ijms25052763>.
40. Hashim N, Babiker R, Mohammed R, Rehman MM, Chaitanya NC, Gobara B. 2024. NLRP3 Inflammasome in autoinflammatory diseases and periodontitis advance in the management. *J. Pharm. Bioallied Sci.* **16**: S1110-S1119. https://doi.org/10.4103/jpbs.jpbs_1118_23.
41. Xu J, Nunez G. 2023. The NLRP3 inflammasome: activation and regulation. *Trends Biochem. Sci.* **48**: 331-344. <https://doi.org/10.1016/j.tibs.2022.10.002>.
42. Xue F, Shu R, Xie Y. 2015. The expression of NLRP3, NLRP1 and AIM2 in the gingival tissue of periodontitis patients: RT-PCR study and immunohistochemistry. *Arch. Oral Biol.* **60**: 948-958. <https://doi.org/10.1016/j.archoralbio.2015.03.005>.
43. Tang B, Liu D, Chen L, Liu Y. 2020. NLRP3 inflammasome inhibitor MCC950 attenuates primary dysmenorrhea in mice via the NF-kappaB/COX-2/PG pathway. *J. Inflamm. (Lond)* **17**: 22. <https://doi.org/10.1186/s12950-020-00251-7>.
44. Zhao W, Ma L, Cai C, Gong X. 2019. Caffeine inhibits NLRP3 inflammasome activation by suppressing MAPK/NF-kappaB and A2aR signaling in LPS-induced THP-1 macrophages. *Int. J. Biol. Sci.* **15**: 1571-1581. <https://doi.org/10.7150/ijbs.34211>.
45. Liu X, Zhang R, Fan J, Chen Y, Wang H, Ge Y, *et al.* 2023. The role of ROS/p38 MAPK/NLRP3 inflammasome cascade in arsenic-induced depression-/anxiety-like behaviors of mice. *Ecotoxicol. Environ. Saf.* **261**: 115111. <https://doi.org/10.1016/j.ecoenv.2023.115111>.
46. Shin JN, Rao L, Sha Y, Abdel Fattah E, Hyser J, Eissa NT. 2021. p38 MAPK activity is required to prevent hyperactivation of NLRP3 inflammasome. *J. Immunol.* **207**: 661-670. <https://doi.org/10.4049/jimmunol.2000416>.
47. Jang EJ, Jeong HO, Park D, Kim DH, Choi YJ, Chung KW, *et al.* 2015. Src tyrosine kinase activation by 4-hydroxynonenal upregulates p38, ERK/AP-1 signaling and COX-2 expression in YPEN-1 Cells. *PLoS One* **10**: e0129244. <https://doi.org/10.1371/journal.pone.0129244>.
48. Tsukasaki M. 2021. RANKL and osteoimmunology in periodontitis. *J. Bone Miner. Metab.* **39**: 82-90. <https://doi.org/10.1007/s00774-020-01165-3>.
49. De Leon-Oliva D, Barrena-Blazquez S, Jimenez-Alvarez L, Fraile-Martinez O, Garcia-Montero C, Lopez-Gonzalez L, *et al.* 2023. The RANK-RANKL-OPG system: a multifaceted regulator of homeostasis, immunity, and cancer. *medicina (Kaunas)*. **59**: 1752. <https://doi.org/10.3390/medicina59101752>.
50. Ko SY. 2012. Myricetin suppresses LPS-induced MMP expression in human gingival fibroblasts and inhibits osteoclastogenesis by downregulating NFATc1 in RANKL-induced RAW 264.7 cells. *Arch. Oral Biol.* **57**: 1623-1632. <https://doi.org/10.1016/j.archoralbio.2012.06.012>.
51. Zhang D, Zhang J, Fong C, Yao X, Yang M. 2012. Herba epimedii flavonoids suppress osteoclastic differentiation and bone resorption by inducing G2/M arrest and apoptosis. *Biochimie* **94**: 2514-2522. <https://doi.org/10.1016/j.biochi.2012.06.033>.